XML 62 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2
Organization and Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2012
USD ($)
Target
Jun. 30, 2012
USD ($)
Jan. 31, 2012
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
AccountingUnit
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Drug
Category
Stage
Partner
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Revenue Recognition [Abstract]                                
Number of categories of milestone events | Category                           3    
Number of stages of life-cycle of drugs | Stage                           3    
Number of partners that exercised option to license drugs | Partner                           3    
Number of drugs licensed under option in collaboration agreements | Drug                           3    
Revenue earned           $ 160,349 $ 110,927 $ 38,470 $ 36,874 $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 346,620 $ 283,703 $ 214,161
AstraZeneca, Biogen and Janssen [Member]                                
Revenue Recognition [Abstract]                                
Revenue earned                           $ 98,000    
Minimum [Member]                                
Revenue Recognition [Abstract]                                
Period to complete IND-enabling animal studies                           12 months    
Period to complete Phase 1 clinical trial                           1 year    
Period to complete Phase 2 clinical trial                           1 year    
Period to complete Phase 3 clinical trial                           2 years    
Period to prepare and submit regulatory filings                           6 months    
Period to obtain marketing authorization from applicable regulatory agency                           1 year    
Pre-specified product sales threshold included in commercialization milestones                           $ 1,000,000    
Maximum [Member]                                
Revenue Recognition [Abstract]                                
Period to complete IND-enabling animal studies                           18 months    
Period to complete Phase 1 clinical trial                           2 years    
Period to complete Phase 2 clinical trial                           3 years    
Period to complete Phase 3 clinical trial                           4 years    
Period to prepare and submit regulatory filings                           12 months    
Period to obtain marketing authorization from applicable regulatory agency                           2 years    
Bayer [Member]                                
Revenue Recognition [Abstract]                                
Upfront payment received                       $ 100,000        
Number of units of accounting | AccountingUnit                       3        
Upfront payment allocated to exclusive license $ 91,200                     $ 91,200        
Upfront payment allocated to ongoing development services 4,300                     4,300        
Upfront payment allocated to delivery of API 4,500                     $ 4,500        
Assumed percentage change in estimated selling price                       10.00%        
Percentage change in earned revenue based on assumed change in estimated selling price                       1.00%        
Amount by which earned revenue would change based on assumed change in estimated selling price                       $ 900        
Revenue earned $ 91,200                         $ 5,400 93,400  
Collaboration Agreements with Biogen [Member]                                
Revenue Recognition [Abstract]                                
Revenue earned                           $ 207,900 $ 106,200 $ 123,200
Collaboration Agreements with Biogen [Member] | Minimum [Member]                                
Revenue Recognition [Abstract]                                
Number of drugs that can be licensed under option in collaboration agreements | Drug                           1    
SPINRAZA [Member]                                
Revenue Recognition [Abstract]                                
Upfront payment recorded as deferred revenue         $ 29,000                      
DMPK [Member]                                
Revenue Recognition [Abstract]                                
Upfront payment recorded as deferred revenue       $ 12,000                        
Neurology [Member]                                
Revenue Recognition [Abstract]                                
Upfront payment recorded as deferred revenue     $ 30,000                          
Number of targets | Target     3                          
Strategic Neurology [Member]                                
Revenue Recognition [Abstract]                                
Upfront payment recorded as deferred revenue   $ 100,000                            
Term of collaboration agreement                           6 years